Literature DB >> 9799800

Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration.

C D Jolley1, L A Woollett, S D Turley, J M Dietschy.   

Abstract

The major net flux of cholesterol in the intact animal or human is from the peripheral organs to the liver. This flux is made up of cholesterol that is either synthesized in these peripheral tissues or taken up as lipoprotein cholesterol. This study investigates whether it is the concentration of apolipoprotein (apo) A-I or high density lipoprotein in the plasma that determines the magnitude of this flux or, alternatively, whether events within the peripheral cells themselves regulate this important process. In mice that lack apoA-I and have very low concentrations of circulating high density lipoprotein, it was found that there was no accumulation of cholesterol in any peripheral organ so that the mean sterol concentration in these tissues was the same (2208 +/- 29 mg/kg body weight) as in control mice (2176 +/- 50 mg/kg). Furthermore, by measuring the rates of net cholesterol acquisition in the peripheral organs from de novo synthesis and uptake of low density lipoprotein, it was demonstrated that the magnitude of centripetal sterol movement from the peripheral organs to the liver was virtually identical in control animals (78 +/- 5 mg/day per kg) and in those lacking apoA-I (72 +/- 4 mg/day per kg). These studies indicate that the magnitude of net sterol flux through the body is not related to the concentration of high density lipoprotein or apolipoprotein A-I in the plasma, but is probably determined by intracellular processes in the peripheral organs that dictate the rate of movement of cholesterol from the endoplasmic reticulum to the plasma membrane.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9799800

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  28 in total

1.  Is it time to modify the reverse cholesterol transport model?

Authors:  A R Tall; N Wang; P Mucksavage
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

2.  HDL action on the vascular wall: is the answer NO?

Authors:  Philip W Shaul; Chieko Mineo
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

Review 3.  A new framework for reverse cholesterol transport: non-biliary contributions to reverse cholesterol transport.

Authors:  Ryan-E Temel; J-Mark Brown
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

Review 4.  Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.

Authors:  Emil M deGoma; Rolando L deGoma; Daniel J Rader
Journal:  J Am Coll Cardiol       Date:  2008-06-10       Impact factor: 24.094

Review 5.  A new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretion.

Authors:  Ryan E Temel; J Mark Brown
Journal:  Trends Pharmacol Sci       Date:  2015-04-27       Impact factor: 14.819

6.  Response of lipid, lipoprotein-cholesterol, and electrophoretic characteristics of lipoproteins following a single bout of aerobic exercise in women.

Authors:  Joshua S Wooten; Kyle D Biggerstaff; Caroline Anderson
Journal:  Eur J Appl Physiol       Date:  2008-05-29       Impact factor: 3.078

7.  In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1.

Authors:  Adriaan G Holleboom; Lily Jakulj; Remco Franssen; Julie Decaris; Menno Vergeer; Joris Koetsveld; Jayraz Luchoomun; Alexander Glass; Marc K Hellerstein; John J P Kastelein; G Kees Hovingh; Jan Albert Kuivenhoven; Albert K Groen; Scott M Turner; Erik S G Stroes
Journal:  J Lipid Res       Date:  2013-05-06       Impact factor: 5.922

8.  Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo.

Authors:  YuZhen Zhang; Jaqueline R Da Silva; Muredach Reilly; Jeffrey T Billheimer; George H Rothblat; Daniel J Rader
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 9.  Shifting gears: liver SR-BI drives reverse cholesterol transport in macrophages.

Authors:  Astrid E van der Velde; Albert K Groen
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

10.  Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo.

Authors:  Frank M Sacks; Lawrence L Rudel; Adam Conner; Hassibullah Akeefe; Gerhard Kostner; Talal Baki; George Rothblat; Margarita de la Llera-Moya; Bela Asztalos; Timothy Perlman; Chunyu Zheng; Petar Alaupovic; Jo-Ann B Maltais; H Bryan Brewer
Journal:  J Lipid Res       Date:  2009-01-14       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.